107P Systematic characterization of MET activating mutations in non-small cell lung cancer

Abstract

Alterations in mesenchymal epithelial transition factor (MET) as primary oncogenic drivers or secondary resistance mechanisms to tyrosine kinase inhibitors (TKI) often involve distinct MET mutation subtypes. While MET activating mutations primarily mediates resistance to MET TKIs, increasing evidence suggest that MET activating mutations also exist in the primary tissues. The molecular signatures and clinical relevance of MET activating mutations remain to be elucidated.